SAVING LIVES BY DESIGNING BETTER VACCINES
EVA Therapeutics aims to become a global leader in computational vaccine design for LMIC-focused diseases, accelerating solutions for neglected pathogens and supporting equitable vaccine access worldwide. Over time, EVA (an acronym for Equitable Vaccine Access) will build a pipeline of affordable, scalable vaccine candidates ready for downstream partners to manufacture and distribute in LMIC markets.
Welcome
Formerly called EpIVax Therapeutics, EVA Therapeutics (new name) has the same for-profit corporate structure as before, including the same board of Directors, the same investors, and the same shareholders.
OUR MISSION
Improving Access to Effective Vaccines against Diseases that Disproportionately Affect LMIC
OUR VISION
State of the art computational vaccine and immunotherapeutic design will put production and distribution of life-saving vaccines within reach for residents of LMIC.
OUR VALUES
Committed
Dedicated to improving lives everywhere
Innovative
Pursuing innovative ideas to consistently advance discovery
Value driven
Serving our patients and the science community
Accountable
Quality and safety are our top priorities